Literature DB >> 30904030

Comorbidity in multiple sclerosis: Past, present and future.

Ruth Ann Marrie1.   

Abstract

PURPOSE: Multiple sclerosis (MS) is an inflammatory and degenerative condition affecting the central nervous system. Like many neurologic diseases, it is chronic and incurable, and confers a substantial burden on affected individuals, their families and society. Although many individuals suffering from a serious chronic disease also suffer from comorbid conditions, the important consequences of their interaction often receive little attention. This was particularly true for MS two decades ago. Broadening our perspective by better understanding the effects of comorbidity on an individual with a particular chronic disease offers us an opportunity to improve understanding of prognosis, personalize disease management, develop new therapeutic approaches and illuminate the pathophysiology of disease. SOURCE: Studies examining the incidence, prevalence and outcomes related to comorbidity in MS will be discussed, along with areas requiring further investigation.
CONCLUSION: Comorbidity is highly prevalent in MS throughout the disease course. Comorbid conditions, including depression, anxiety, hypertension, hyperlipidemia, diabetes and chronic lung disease, adversely affect a broad range of outcomes. Less is known about the effects of MS on outcomes related to these comorbid conditions. These findings highlight an urgent need to determine how to best prevent and treat comorbidity in MS.

Entities:  

Mesh:

Year:  2019        PMID: 30904030     DOI: 10.25011/cim.v42i1.32383

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  10 in total

1.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

2.  A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis.

Authors:  Antonio Reia; Martina Petruzzo; Fabrizia Falco; Teresa Costabile; Matteo Conenna; Antonio Carotenuto; Maria Petracca; Giuseppe Servillo; Roberta Lanzillo; Vincenzo Brescia Morra; Marcello Moccia
Journal:  Brain Sci       Date:  2021-04-16

3.  The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis.

Authors:  Niklas Frahm; Michael Hecker; Silvan Elias Langhorst; Pegah Mashhadiakbar; Marie-Celine Haker; Uwe Klaus Zettl
Journal:  Ther Adv Neurol Disord       Date:  2020-12-19       Impact factor: 6.570

4.  Pathways to cures for multiple sclerosis: A research roadmap.

Authors:  Bruce F Bebo; Mark Allegretta; Douglas Landsman; Kathy M Zackowski; Fiona Brabazon; Walter A Kostich; Timothy Coetzee; Alexander Victor Ng; Ruth Ann Marrie; Kelly R Monk; Amit Bar-Or; Caroline C Whitacre
Journal:  Mult Scler       Date:  2022-03       Impact factor: 6.312

5.  Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.

Authors:  Jagadeswara Rao Earla; George J Hutton; J Douglas Thornton; Hua Chen; Michael L Johnson; Rajender R Aparasu
Journal:  Explor Res Clin Soc Pharm       Date:  2021-05-05

6.  Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls.

Authors:  Selma Tekin; Levent Sinan Bir; Esin Avci; Hande Şenol; Işık Tekin; Ufuk Çınkır
Journal:  Cureus       Date:  2022-07-18

7.  Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis.

Authors:  Jane Louisa Debus; Paula Bachmann; Niklas Frahm; Pegah Mashhadiakbar; Silvan Elias Langhorst; Barbara Streckenbach; Julia Baldt; Felicita Heidler; Michael Hecker; Uwe Klaus Zettl
Journal:  Ther Adv Chronic Dis       Date:  2022-08-04       Impact factor: 4.970

8.  Altered muscle oxidative phenotype impairs exercise tolerance but does not improve after exercise training in multiple sclerosis.

Authors:  Jan Spaas; Richie P Goulding; Charly Keytsman; Lena Fonteyn; Jack van Horssen; Richard T Jaspers; Bert O Eijnde; Rob C I Wüst
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-08-04       Impact factor: 12.063

Review 9.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014

10.  Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.

Authors:  Jagadeswara R Earla; George J Hutton; J Douglas Thornton; Hua Chen; Michael L Johnson; Rajender R Aparasu
Journal:  Patient Prefer Adherence       Date:  2020-11-04       Impact factor: 2.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.